Tryptamine compositions for enhancing neurite outgrowth
Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
1. A method of treating serotonin (5-hydroxytryptamine, 5-HT) receptor disorders, neurological diseases, or augmenting neurogeneration in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising:
0.5-4 mg of norpsilocin or a salt or combinations thereof; and
0.5-4 mg of niacin.
2. The method of claim 1 , wherein the composition further comprises an extract of or isolate from Hericium erinaceus.
3. The method of claim 1 , wherein the composition further comprises one or more cannabinoids in pure form or extracts or isolates from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis.
4. The method of claim 1 , wherein the composition comprises one or more pharmaceutically acceptable excipients.
5. The method of claim 1 , wherein the composition is a powder admixture, liquid, suspension, or emulsion.
6. The method of claim 1 , wherein the serotonin (5-hydroxytryptamine, 5-HT) receptor disorder comprises depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression, bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depressions, situational depression, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, attention deficit/hyperactivity disorder, substance abuse disorders or combinations thereof.